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ABSTRACT
Objective: The objective of this study was to compare the efficacy of tranexamic acid 10 mg/kg and 15 mg/kg in reducing bleeding and transfusions 
in total knee arthroplasty.
Methods: After approval from the Institutional Ethics Committee, KMC, Mangaluru, 88 patients fulfilling the inclusion criteria of this study undergoing 
total knee replacements were informed of the study details and consent was obtained for the same. They were randomized into two groups using 
computer-generated block randomization, i.e., Group A and Group B, and were administered tranexamic acid 10 mg/kg and 15 mg/kg intravenously, 
respectively. Intraoperatively, hemodynamic parameters were noted. Postoperatively, hemoglobin levels were assessed on days 1 and 3. Transfusions, 
thromboembolic complications, and duration of hospital stay were noted.
Results: Of the 88 participants of the trial, 44 in Groups A and B each, there were no significant differences in the parameters observed in this 
study such as intraoperative hemodynamic changes, post-operative fall in hemoglobin on day 3, number of patients requiring transfusions, number 
of thromboembolic events, and duration of hospital stay. A significant p-value was observed in the fall in hemoglobin in the post-operative day 3 
(p=0.043).
Conclusion: About 15 mg/kg tranexamic acid proved to have a lesser fall in hemoglobin on day 3 postoperatively when compared to the 10 mg/kg 
group. However, the fall of hemoglobin on day 3 was statistically significant and warranted a blood transfusion in two patients in the 10 mg/kg group 
but did not prolong their hospital stay.
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INTRODUCTION
During the past five decades, total knee arthroplasty (TKA) has been 
one among the most clinically successful surgeries to be developed. 
Hence, it has become the most common orthopedic procedure to be 
performed. Further, considerable growth in numbers of the TKA has 
been projected in the future [1].
TKA is usually performed on arthritic knees not responding to 
conservative therapies that include medical, orthotic, and/or 
rehabilitative methods [2,3]. The aim of conservative therapies is 
to achieve symptom relief and alteration of disease progression. 
Unfortunately, they do not offer long-lasting relief [2]. Patient age, 
severity of osteoarthritis and response to other treatment modalities 
are considered as the key factors in selecting the patients for total knee 
arthroplasty [4-6]. The goals of TKA include reducing pain, returning to 
regular activities of daily living, and achieving a mechanical alignment 
close to normal [7].
The anesthesia and post-operative care for these patients, often 
belonging in the geriatric age group, have evolved over time along with 
the population and techniques of surgery. In the early days, general 
anesthesia was preferred for these procedures. However, five decades 
have passed since then, and due to the wider safety margins and better 
patient outcomes, regional techniques are preferred now [8].
The adverse events and complications include bleeding [9,10], 
thromboembolic disease, wound complication, vascular injury, 
readmission, revision, reoperation, and death [1]. Post-operative bleeding 
and the need for blood transfusions, as a result, have always been a cause 
of concern among many clinicians. The use of tranexamic acid to counter 
this has received special attention among patients requiring orthopedic 
surgery, with numerous studies showing clinical efficacy and cost-
effectiveness [11]. Fibrinolysis occurs by surgical trauma, and it is further 
worsened by the use of a tourniquet which is one of the commonly 
applied non-pharmacological methods to control bleeding [12-14].
Tranexamic acid is a synthetic analog of lysine, an amino acid, and 
acts competitively by blocking the lysine binding site of plasminogen. 
This leads to the inhibition of fibrinolysis [15,16]. There are four 
methods of administering tranexamic acid to reduce blood loss: Oral, 
intramuscular, intravenous, and intra-articular. The time taken for 
maximum plasma levels of tranexamic acid to be reached has been 
reported to be 30 min for intramuscular, 2 h for oral, and 5–15 min for 
intravenous administration [17]. The use of tranexamic acid has shown 
to reduce perioperative blood loss, blood transfusions, and associated 
costs in major orthopedic surgery [18,19]. Tranexamic acid is usually 
well-tolerated, gastrointestinal side effects like nausea and diarrhea 
are the most common adverse events [20], the risk of thromboembolic 
complications related to tranexamic acid use has been controversial but 
is present significantly in those with alternative risk factors that include 
previous thrombotic events and oral hormonal contraceptive use. Seizure 
activity following  tranexamic acid use is very  rare [21,22].
However, as many centers seemed to rely on empirical doses such as 
1 g or 2 g of tranexamic acid instead of more tailored ones, we tried to 
compare two regimens of tranexamic acid, i.e. 10 mg/kg and 15 mg/kg 
in ASA 1 and ASA 2 patients undergoing total knee replacements while 
we checked for post-operative indicators of bleeding and transfusions 
in TKA surgeries.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i3.31006
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METHODS
This was a prospective, randomized controlled trial done after approval 
from the Institutional Ethics Committee, in hospitals associated with 
Kasturba Medical College, Mangalore, from September 2016 to June 
2018. 88 ASA Class 1 and 2 patients aged 40–70 years, fulfilling the 
aforementioned inclusion criteria, posted for elective TKA were chosen 
using computer-generated block randomization and were divided into two 
groups: Group A and Group B, i.e., 10 mg/kg and 15 mg/kg, respectively. 
They also had no known hypersensitivity to tranexamic acid and no 
history of coagulation disorders. Patients who refused had preoperative 
hemoglobin <10 mg/dL, and a previous TKA was excluded from the study.
All patients underwent detailed pre-anesthetic evaluation. The study 
protocol was explained to the patients and written informed consent 
was obtained. A fasting period of 6 h before the surgery was advised. 
After shifting the patients to the operating room, monitors such as 
electrocardiography, non-invasive blood pressure, and SPO2 were 
connected and the baseline hemodynamics were charted. A peripheral 
intravenous line was secured and preloaded with 500 ml crystalloids. 
All the patients were subjected to combined spinal-epidural anesthesia 
using combined spinal-epidural needle where 2 ml of 0.5% bupivacaine 
in dextrose solution was given for subarachnoid block and an epidural 
catheter is guided in and fixed at the point where 5-cm length of the 
catheter is inside the space. The epidural infusion was activated after 1 h 
with 0.5% bupivacaine at 5 ml/h until the end of surgery. Tranexamic 
acid was given in two doses based on their randomly allocated 
group 20 min before the skin incision and just before tourniquet 
release. After the completion of the surgery, the patients were shifted 
to the post-operative room and vitals were monitored. Hemoglobin 
levels on post-operative day 1 and day 3, perioperative hemodynamic 
variation, and duration of hospital stay were measured and charted.










n is the sample size
Zα =1.96 at 95% confidence interval
Zβ = 0.84 at 80% power
σ = standard deviation
d =mean
With 95% Confidence Interval, 80% power to ther study.
The data were analyzed using Student’s unpaired t-test and Chi-square 
test. A statistical package SPSS version 17.0 was used to do this analysis 
and *p<0.05 was considered to be statistically significant.
RESULTS
As shown in Table 1, The study population comprised 88 patients with 
a mean age of 64.44 years (standard deviation [SD] - 4.966) in Group A 
and 62.73 in Group B (SD - 4.505) with majority of patients in Group A 
who were in the age group of 61–65 years (43.18%) and those of 
Group B who were in the age group of 61–65 (45.45%). These data are 
statistically not significant with p=0.090
As shown in Table 2, in Group A, 72.73% of patients were female and 
27.27% of patients were male. In Group B, 50.09% of patients were 
female and 40.91% were male. The gender distribution between the 
two groups was statistically not significant, with p=0.090
As shown in Table 3, all patients belonged to the ASA 2 group.
As exhibited in Table 4, there were no significant differences in the duration 
of hospital stay in Groups A and B. The difference between the duration of 
stay between two groups was statistically not significant, p=0.552.
Table 5 shows that 4.54% of patients in Group A required transfusion 
of blood as their hemoglobin was <7 g/dL as compared to 0 in Group B. 
This value was statistically insignificant with p=0.238.
In Group A, mean hemoglobin level preoperatively was 11.58 with a SD 
of ±1.359, mean hemoglobin on postoperatively day 1 was 10.829 with 
SD of ±1.7739, mean hemoglobin on post-operative day 3 was 10.86 
with SD of±1.218, while Group B showed mean hemoglobin levels 
of 12.2 with SD±1.187 pre-operatively, mean hemoglobin on post-
operative day 1 was 11.427 with SD±0.8167, and mean hemoglobin on 
post-operative day 3 was 10.89 with SD±1.153.
As shown in Table 6, the fall in hemoglobin on post-operative day 3 
was more in Group A when compared to Group B. This was statistically 
significant p=0.043.
Table 1: Age‑wise division of patients
Group Group A Group B Total
Age (years)
40–55 1 (2.27) 0 (0.00) 18 (1.13)
56–60 7 (15.90) 5 (11.36) 14 (13.63)
61–65 19 (43.18) 20 (45.45) 32 (44.31)
65–70 17 (38.63) 19 (43.18) 36 (40.90)
Total 44 (100.0) 44 (100.0) 88 (100.0)
Table 2: Gender‑wise distribution of patients
Group Group A Group B Total
Sex
Female 32 (72.73) 26 (50.09) 58 (65.90)
Male 12 (27.27) 18 (40.91) 30 (34.09)
Total 44 (100.0) 44 (100.0) 88 (100.0)
Table 3: The ASA status‑wise distribution of patients
Group Group A Group B Total
ASA 2 44 (100.0) 44 (100.0) 88 (100.0)
Table 4: Duration of hospital stay
Groups Group A Group B
Duration of hospital stay in days
5 1 (2.27) 2 (4.54)
6 14 (31.81) 22 (50)
7 19 (43.18) 10 (22.72) 
8 and above 10 (22.72) 10 (22.72)
Table 5: Transfusion rates of both groups
Groups Group A Group B
Transfusion
No 42 (95.46) 44 (100)
Yes 2 (4.54) 0 (0)
Table 6: Mean hemoglobin on pre‑operative day 1 and 3 of the 
study groups
Groups Group A Group B p
Hemoglobin levels
Pre-operative 11.88 12.2 0.419
Day 1 10.83 11.43 0.319
Day 3 10.86 10.89 0.043
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Hemodynamic parameters
There were no significant changes in both groups observed.
Thromboembolic phenomenon
There were no reported cases of thromboembolism in either group.
DISCUSSION
The main indication for TKA is to relieve pain caused by arthritis that is 
significant and disabling. Bleeding intraoperatively and postoperatively 
is one of the main concerns in TKA. The loss of blood could range 
between 800 ml and 1800 ml. Perioperative transfusions increase the 
cost of the treatment and the risks of infection and allergic reactions. 
Since the report by Benoni et al. [23], different studies have been 
published on the efficacy of tranexamic acid in reducing perioperative 
blood loss in total joint arthroplasty.
Our study compared the efficacy of two doses of tranexamic acid, 
i.e., 10 mg/kg versus 15 mg/kg in reducing bleeding and transfusions in 
total knee replacement surgeries.
There were no significant differences in the intraoperative 
hemodynamic changes in the parameters observed such as heart rate, 
blood pressure, SpO2, and respiratory rate in the participants of both 
10 mg/kg and 15 mg/kg group. There were no thromboembolic events 
in any participant of this study. There were no statistically significant 
differences in the duration of hospital stay between both groups.
Two patients in the 10 mg/kg group required blood transfusions, as 
their post-operative day 3 hemoglobin was <7 mg/dL. However, this 
was deemed statistically significant. Another study by Good et al. [24] 
who conducted a trial with placebo and tranexamic acid 10 mg/kg iv 
showed that three patients in their study required blood transfusions 
even though they received tranexamic acid. This is consistent with the 
10 mg/kg group in our study. Another study by Cid and Lozano [25] 
reaffirms with this as two patients in their 10 mg/kg tranexamic acid 
group received blood transfusions as compared to the placebo group 
where 7 patients were transfused with blood products.
Our study observed a significant post-operative fall in hemoglobin 
on day 3 in the 10 mg/kg group when compared to the 15 mg/kg 
group. A study by Benoni et al. [23] showed that a dose of 10 mg/kg 
of tranexamic acid reduced the number of patients receiving a blood 
transfusion and the fall in post-operative hemoglobin. Marra et al. [26] 
reported that no significant differences in maximum loss of hemoglobin 
were observed between the different treatment groups they studied 
where the intravenous group received 10 mg/kg tranexamic acid. 
However, their study suggests that a combination of intra-articular and 
intravenous tranexamic acid had the least fall in hemoglobin. A study 
by Tanaka et al. [27] where tranexamic acid was given once before 
surgery and once on deflation of the tourniquet reduced bleeding and 
transfusions. A similar study by Orpen et al. [28] where 15 mg/kg of 
tranexamic acid given at the time of cementing the prosthesis, before 
deflation of the tourniquet in TKA, showed that a dose of 15 mg/kg 
given in such a manner effectively reduced bleeding and transfusions. 
This is concurrent with our findings where 15 mg/kg group showed 
a reduced fall in hemoglobin on post-operative day 3 and had nil 
transfusions compared to the 10 mg/kg group.
Ralley et al. [29] studied the effect of one 20 mg/kg dose of tranexamic 
acid given intraoperatively which was effective in reducing the 
perioperative decrease in hemoglobin and red blood cell transfusion 
rates in patients undergoing TKA. However, our study showed that 
15 mg/kg was an effective dose as we had nil transfusions and reduced 
post-operative hemoglobin fall in our study group.
Two studies by Lin et al. [30] and Maniar et al. [31] showed that two 
doses of 10 mg/kg in TKA were more effective than single doses of 
the same drug. As our study compared two doses of tranexamic acid 
administered twice during the surgery, we found that two intravenous 
doses of 15 mg/kg are better than the 10 mg/kg.
Poeran et al. [7] compared four study groups with none, ≤o g, 2 g, and ≥ g 
of tranexamic acid, and Castro-Menéndeza et al. [32] conducted a study 
with empirical doses of tranexamic acid as high as 2 g and found that 
2 g of tranexamic acid iv had the best effectiveness and safety profile. 
Morrison et al. [33] compared 15 mg/kg versus 30 mg/kg intravenous 
tranexamic acid. While our study did not go higher than 15 mg/kg in 
terms of dosing, we have found comparable results with the same in 
terms of rates of transfusion and fall in hemoglobin.
CONCLUSION
There were no significant differences in the intraoperative 
hemodynamic changes in the parameters observed such as heart 
rate, blood pressure, SpO2, and respiratory rate in the participants of 
both 10 mg/kg and 15 mg/kg group. A statistically significant p-value 
(p=0.043) was observed in the fall in hemoglobin on post-operative day 
3 in the 10 mg/kg group as compared to the 15 mg/kg group. Hence, we 
conclude that 15 mg/kg was more effective than 10 mg/kg in reducing 
bleeding and transfusions in TKA.
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